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Summary 38 
Reasons for performing study: Equine grass sickness (EGS) is of unknown aetiology. 39 
Despite some evidence suggesting that it represents a toxico-infection with Clostridium 40 
botulinum types C and/or D, the effect of EGS on the functional targets of botulinum 41 
neurotoxins (BoNTs), namely the soluble N-ethylmaleimide-sensitive factor attachment 42 
receptor (SNARE) proteins, is unknown. Further, while it is commonly stated that, unlike 43 
EGS, equine botulism is not associated with autonomic and enteric neurodegeneration, this 44 
has not been definitively assessed.  45 
Objectives: To determine (a) whether botulism causes autonomic and enteric 46 
neurodegeneration, and (b) the effect of EGS on the expression of SNARE proteins within 47 
cranial cervical ganglion [CCG] and enteric neuronal perikarya. 48 
Methods: Light microscopy was used to compare the morphology of neurons in 49 
haematoxylin-eosin stained sections of CCG and ileum from 6 EGS horses, 5 botulism horses 50 
and 6 control horses. Immunohistochemistry was used to compare the expression of 51 
synaptosomal-associated protein-25 (SNAP-25), synaptobrevin (Syb) and syntaxin (Syn) 52 
within CCG neurons, and of Syb in enteric neurons, from horses with EGS, horses with 53 
botulism and control horses. The concentrations of these SNARE proteins in extracts of CCG 54 
from EGS and control horses were compared using quantitative fluorescent western blotting 55 
(QFWB).  56 
Results: EGS, but not botulism, was associated with autonomic and enteric 57 
neurodegeneration and with increased immunoreactivity for SNARE proteins within neuronal 58 
perikarya. QFWB confirmed increased concentrations of SNAP-25, Syb and Syn within CCG 59 
extracts from EGS versus control horses, with the increases in the latter two proteins being 60 
statistically significant.  61 
 3 
Conclusions and potential relevance: The occurrence of autonomic and enteric 62 
neurodegeneration, and increased expression of SNARE proteins within neuronal perikarya, in 63 
EGS but not botulism, suggests that EGS may not be caused by BoNTs. Further investigation 64 
of the aetiology of EGS is therefore warranted.  65 
 66 
Keywords: horse; grass sickness; botulism; SNARE proteins; SNAP-25; syntaxin; 67 
synaptobrevin. 68 
 69 
Introduction 70 
Equine grass sickness (EGS) is widely hypothesised to be a toxico-infectious form of 71 
botulism, whereby a dietary trigger induces intestinal overgrowth of Clostridium botulinum C 72 
and/or D, with resultant in vivo production of botulinum neurotoxins (BoNTs) [1-4]. 73 
Consistent with this hypothesis, EGS is associated with an increased frequency of detection of 74 
C. botulinum type C and BoNT/C1 within the intestinal tract [2]. Furthermore, increased 75 
serum levels of antibodies specific for botulinum surface antigens and for BoNT/C1 have 76 
been detected in horses with recent exposure to EGS [3], and have been associated with 77 
increased protection against EGS [4]. A botulinum vaccine appeared to provide protection 78 
against EGS [1]. It has also been hypothesised that botulinum C2 toxin, an ADP-ribosylating 79 
toxin produced by C. botulinum C and D, may contribute to neurodegeneration in EGS [2,3]. 80 
In all species, BoNTs cause generalised neuromuscular dysfunction by cleaving the soluble N-81 
ethylmaleimide sensitive fusion attachment receptor (SNARE) proteins which are essential for 82 
presynaptic vesicle exocytosis, leading to accumulation of synaptic vesicles in nerve terminal 83 
boutons and the consequent failure of synaptic transmission [5]. BoNTs are remarkably 84 
specific proteases, with BoNT/B, /D, /F and /G cleaving the vesicle protein synaptobrevin 85 
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(Syb), BoNT/A and /E cleaving the plasma membrane protein SNAP-25 and BoNT/C 86 
cleaving both synaptosomal-associated protein-25 (SNAP-25) and the peripheral plasma 87 
membrane protein syntaxin (Syn) [6]. 88 
The authors question the proposed role of BoNTs in EGS, given the obvious differences in 89 
clinical signs between EGS and neuroparalytic botulism [7]. Furthermore, it is anecdotally 90 
stated that the autonomic and enteric neurodegeneration which characterises EGS does not 91 
occur in equine botulism [7,8], although has not been definitively assessed. The aim of this 92 
study was to investigate further the potential role of BoNTs in EGS by using (a) conventional 93 
histological examination of CCG and ileal neurons to determine whether botulism causes 94 
autonomic and enteric neurodegeneration resembling that which characterises EGS, (b) 95 
immunohistochemistry to compare the expression of SNARE proteins in cranial cervical 96 
ganglion [CCG] neurons [SNAP-25, Syn, Syb] and enteric neurons [Syb], in EGS, botulism 97 
and control horses, and (c) quantitative fluorescent western blotting [QFWB] to compare the 98 
concentration of SNARE proteins in extracts of CCG from EGS and control horses.  99 
 100 
 101 
Materials and methods  102 
Samples 103 
The study was approved by both the University of Edinburgh Ethical Review Committee and 104 
an ethical review committee within the United Arab Emirates (Permit 550J53). EGS and 105 
control horse samples were collected with owners' consent from horses that were subjected to 106 
euthanasia on humane grounds. CCG and ileum samples were collected from 6 EGS (4 acute 107 
EGS and 2 subacute EGS; median age 7 years, range 2-20) and 6 control (11, 6-15 years) 108 
mixed-breed and mixed-gender horses (Supplementary file 1). EGS was categorised as 109 
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previously described and confirmed by necropsy including histopathological examination of 110 
cranial cervical ganglia [9]. Control horses were euthanased for reasons other than 111 
neurological disease. Samples were also obtained from 5 horses (median age 11 years, range 112 
6-19 years) with neuroparalytic botulism. One of these horses had a clinical history, clinical 113 
signs, and (negative) post-mortem findings consistent with botulism, although toxin testing 114 
was not performed. Archived formalin fixed tissue blocks of CCG and ileums were also 115 
obtained from a previous historic study conducted in Dubai, from 4 horses which developed 116 
neuroparalytic botulism following oral administration of a bacteria-free supernatant from a 117 
broth culture of C. botulinum type C (C1 and C2 producer). All samples were collected within 118 
3 h of euthanasia. Samples were fixed in 10% neutral buffered formalin and embedded in 119 
paraffin wax for histology and immunohistochemistry. CCG samples for QFWB were rapidly 120 
frozen by immersion on dry ice pellets and stored at -80oC pending analysis. 121 
 122 
Light microscopy 123 
Light microscopy of haematoxylin-eosin stained sections of all samples was used to compare 124 
morphology of CCG and enteric neurons in the 3 groups of horses and determine whether the 125 
neurons from botulism horses had the features of neurodegeneration which characterise EGS 126 
[10].  127 
 128 
Immunohistochemical localisation of SNARE proteins in CCG and enteric neurons from 129 
horses with EGS, horses with botulism and control horses  130 
CCG sections were labelled for SNAP-25, Syn and Syb, while ileum sections were labelled 131 
only for Syb, largely as previously described [11]. Tissues were dewaxed and rehydrated. 132 
Antigen retrieval was performed by heating sections in 250 ml citrate buffer (pH 6.0, 0.01 M) 133 
for 15 min in a pressure cooker, before cooling for 5 min in running water. A commercial 134 
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immunolabelling kita was used according to manufacturer’s instructions. Slides were rinsed 135 
with Tris buffered saline containing 0.5 M Tween pH 7.5 (TBST) and incubated with primary 136 
antibodies overnight at 4oC. Primary antibodies were titrated to identify the lowest dilution 137 
that consistently yielded specific labelling in control horse sections. Primary antibodies were 138 
murine monoclonal anti-SNAP25b diluted 1:1500 in diluentc, murine monoclonal anti-Syn 139 
STX01HPC-1q diluted 1:1600, and murine monoclonal anti-Sybe diluted 1:1600. For negative 140 
control sections, antibody diluentc replaced primary antibody. Slides were rinsed and 141 
incubated with peroxidase blocking agentf for 10 min, horseradish peroxidase-labelled 142 
polymer for 40 min, then substrate-chromogen solutiong for 10 min with rinsing between each 143 
step. Slides were rinsed once in distilled water, counterstained with Harris’s haematoxylin (1 144 
min), dipped in Scott’s tap water substitute, dehydrated, cleared using ethanol then xylene and 145 
mounted under DPX.  146 
 147 
QFWB comparison of concentrations of SNARE proteins in CCG extracts from EGS 148 
and control horses  149 
Unfortunately samples from botulism horses were unavailable for this part of the study. 150 
QFWB was done as previously described [12,13]. Briefly, protein was extracted in RIPA 151 
bufferh containing 0.1% protease inhibitor cocktaili from EGS (n=6) and control (n=6) horse 152 
CCG and the protein concentration determined using the Micro BCA Assayj. CCG proteins 153 
(20μg load) were separated by SDS-polyacrylamide gel electrophoresis on 4–12% precast 154 
NuPage BisTris gradient gelsk and then transferred to PVDF membrane using an iBlot 2 fast 155 
transfer devicek. The membranes were then blocked using Odyssey blocking bufferl and 156 
incubated with primary antibodies according to manufacturers’ instructions (Table 2). 157 
Secondary antibodies (goat anti-rabbit IRDye 680 and donkey anti-mouse IRDye 680l) were 158 
added according to manufacturers’ instructions. Blots were imaged using an Odyssey Infrared 159 
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Imaging Systeml. Scan resolution of the instrument ranges from 21 to 339 µm, and blots were 160 
imaged at 169 µm. Quantification was performed on single channels with the analysis 161 
software provided. Total protein stained gels were loaded in parallel with those used for 162 
membrane transfer, to ensure equal sample loading, and were analysed using the Odyssey 163 
Infrared Imaging systeml as previously described [12]. 164 
 165 
Statistical analysis 166 
Inter-group comparisons of age and QFWB data used, respectively, the Kruskal-Wallis and 167 
unpaired t-tests, with P<0.05 indicating statistical significance. 168 
 169 
Results  170 
There was no significant inter-group difference in age.  171 
 172 
Light microscopy 173 
CCG and enteric neurons from EGS horses, but not control and botulism horses, had 174 
characteristic features of neuronal degeneration, including central to complete chromatolysis 175 
(loss of Nissl substance), neuronal swelling and vacuolation, intracytoplasmic eosinophilic 176 
inclusions, and eccentric and pyknotic nuclei (Fig 1). 177 
 178 
Immunohistochemistry for SNARE proteins in CCG and enteric neurons 179 
The distribution and density of labelling for all three SNARE proteins in CCG neurons was 180 
indistinguishable between control and botulism horses (Fig 2). In these horses, many neurons 181 
were unlabelled while others had faint punctate labelling confined to axons and to clusters of 182 
granules within soma. CCG neurons from EGS horses had variable intensity and distribution 183 
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of labelling, but there was increased intensity of labelling for all three proteins compared with 184 
botulism and control horses. The increased labelling of EGS neurons was most marked for 185 
Syb. EGS neurons had increased labelling throughout the soma or predominantly in the 186 
peripheral perikaryon, and frequently extending into proximal axons (Fig 2). Occasional EGS 187 
neurons had faint labelling that was indistinguishable from that of botulism and control 188 
horses. There was no apparent inter-group difference in the intensity of labelling of axons 189 
within CCG. 190 
Submucosal and myenteric neuronal perikarya from control and botulism horses had fine 191 
granular labelling of Syb (Fig 3) and Syb immunopositive axons were noted in the muscularis, 192 
submucosa and coursing through villi. In EGS, there was increased intensity of Syb labelling 193 
in perikarya of degenerating submucosal and myenteric neurons, and positively labelled axons 194 
were noted in muscularis and submucosa but were virtually absent from villi. 195 
 196 
QFWB analysis 197 
QFWB analysis revealed significantly increased concentrations of Syb (EGS 170533±46910; 198 
control 9973±3123, P=0.0066), Syn (EGS 49575±4172; control 20775 ±2076, P=0.0008) and 199 
non-significantly increased concentrations of SNAP-25 (EGS 132344±54101; control 200 
68751±27102, P-value=0.3238) in CCG extracts from EGS horses compared with controls 201 
(Fig 4).  202 
 203 
Discussion  204 
This study confirmed anecdotal reports [7,8] that CCG and ileal enteric neurones are not 205 
chromatolytic in horses with botulism, in contrast to EGS, suggesting that EGS is unlikely to 206 
be caused by the particular BoNTs which caused neuroparalysis in the neuroparalytic botulism 207 
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cases. Since 4 of 5 botulism cases were associated with BoNT/C1 intoxication, these data are 208 
inconsistent with the hypothesis that EGS is a toxico-infection associated with BoNT/C1 209 
producing C. botulinum, unless this toxin has different mechanisms of action when produced 210 
in vivo during a toxico-infection rather than following oral toxin exposure. Consistent with 211 
these findings, while experimental challenge with BoNT/C or BoNT/E, in vitro or in vivo, can 212 
cause neurodegeneration in other species [14-18], the threshold concentration for cytotoxicity 213 
is estimated to far exceed the lethal dose for humans and animals [19] and there is currently 214 
no evidence that natural (ie non-experimental) exposure to BoNTs can induce the 215 
neurodegeneration which characterises EGS. 216 
Further evidence against a causal role for orally acquired BoNTs in EGS is the observation 217 
that EGS, but not botulism, was associated with increased neuronal expression of three target 218 
proteins for BoNTs, namely Syn, SNAP-25 and Syb. Perikarya of neurons from control horses 219 
and horses with botulism had faint punctate SNARE protein labelling distributed evenly 220 
throughout the cytoplasm, or confined to discrete clusters of granules which were often 221 
located in the juxtanuclear region. The latter may reflect labelling of SNARE proteins within 222 
the Golgi apparatus, since the morphology of the granule clusters resembles that of wheat 223 
germ agglutinin-labelled Golgi membranes [20]. In contrast, most EGS neurons had increased 224 
intensity of labelling of the entire soma, particularly peripherally. EGS horses also had loss of 225 
Syb immunoreactive nerve fibres within ileal mucosa, consistent with the previously reported 226 
profound loss of mucosal PGP 9.5 immunoreactive fibres in this region [21].  227 
Consistent with increased immunoreactivity for SNARE proteins in CCG neuronal perikarya 228 
in EGS, QFWB analysis revealed increased abundance of all 3 SNARE proteins in extracts of 229 
CCG from EGS compared with those from control horses, with inter-group differences in Syb 230 
and Syn concentrations being statistically significant. These findings are consistent with 231 
previous proteomic data which showed increased abundance of SNAP-25 (2.155 fold 232 
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increase) in extracts of EGS versus control CCG; Syn and Syb were not identified in the 233 
proteome in this study [22]. Unfortunately extracts of CCG from horses with botulism were 234 
unavailable for QFWB.  235 
The increased expression of SNARE proteins in EGS neuronal perikarya mirrors that of 236 
synaptophysin, which also accumulates within perikarya of CCG and enteric neurons from 237 
EGS horses, but not in those with botulism [11]. Synaptophysin is an abundant integral 238 
membrane protein of synaptic vesicles, while Syn, SNAP-25 and Syb are synapse-specific 239 
proteins predominantly localised to plasma membranes of axon terminals [23]. These 240 
presynaptic proteins are synthesized in neuronal perikarya, glycosylated in the Golgi apparatus 241 
and transported in a vesicular form to nerve terminals by axonal transport involving the 242 
cytoskeleton [24]. We hypothesise that the accumulation of synaptophysin and the three 243 
SNARE proteins in perikarya of neurons in EGS reflects (a) dysfunction of glycoprotein 244 
processing in the Golgi, (b) failure of axonal transport of protein-containing vesicles to nerve 245 
terminals, and/or (c) upregulation of neuronal synthesis of these proteins. Consistent with the 246 
first two hypotheses, ultrastructural loss of a recognizable Golgi structure is a likely early 247 
event in EGS, and EGS is associated with major perturbations in the cytoskeleton of 248 
autonomic neurons resulting in accumulation of dopamine-β-hydroxylase in neuronal 249 
perikarya [25].  250 
The increased expression of SNARE proteins in neuronal perikarya in EGS, and not in 251 
botulism, is inconsistent with the hypothesis that BoNT/C causes EGS. Indeed, 252 
immunoreactivity of particular intact SNARE proteins at neuromuscular junctions is reduced 253 
following proteolytic cleavage by particular BoNTs [26,27]. The authors are unaware of 254 
reports that these BoNTs cause accumulation of SNARE proteins within neuronal perikarya. 255 
Furthermore, as BoNT/C1 does not alter Golgi ultrastructure or inhibit vesicle trafficking 256 
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within soma [28], it would not be expected to increase the concentration of these proteins in 257 
CCG neuronal perikarya.  258 
While the findings of this study are inconsistent with EGS being caused by BoNT/C1, the data 259 
do not preclude involvement of other botulinum toxins. While the non-neurotoxic C2 and C3 260 
adenosine diphosphate (ADP) ribosylating toxins have been proposed as a cause of 261 
cytoskeletal disruption and neurodegeneration in EGS [2], their involvement in EGS has not 262 
been assessed. While this study included archived tissues from 4 horses with botulism that 263 
had received oral culture supernatant from a C1 and C2 producing strain of C. botulinum, 264 
conclusions regarding the potential involvement of C2 in EGS cannot be made because it is 265 
not known whether the supernatant contained C2. Furthermore, C2 affects a wide range of cell 266 
types [29] and thus appears unlikely to selectively target the specific populations of neurons 267 
undergoing degeneration in EGS. The role of C3 in the pathogenesis of (non-experimental) 268 
diseases, including EGS, is unclear because it lacks an obvious cell-entry mechanism [30]. 269 
Further investigation of the aetiology of EGS is therefore warranted.  270 
 271 
Manufacturers’ addresses 272 
aDakoCytomation EnVision+ System-HRP; DAB K4001, Dako, Ely, UK. 273 
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dab3265, AbCam, Cambridge, UK. 276 
eab11104, AbCam, Cambridge, UK. 277 
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fReal Peroxidase blocker S2023, Dako, Ely, UK. 278 
gImmPact Dab SK4105, Vector Laboratories, Peterborough, UK. 279 
hThermo Scientific, Paisley, UK. 280 
iProtease inhibitor cocktail, Sigma, Gillingham, UK. 281 
jMicro BCA Assay, Pierce, Thermo Scientific, Paisley, UK. 282 
kNuPage BisTris gradient gels, Invitrogen, Thermo Scientific, Paisley, UK. 283 
lLI-Cor Biosciences, Cambridge, UK. 284 
 285 
Figure legends  286 
Figure 1: Light micrograph of CCG (a-c) and enteric myenteric plexus (d-f) neurons from 287 
EGS, botulism and control horses. Neurons from EGS horses (c, f), but not control (a,d) and 288 
botulism (b, e) horses, were frequently degenerate involving chromatolysis (loss of Nissl 289 
substance), neuronal swelling and vacuolation, intracytoplasmic eosinophilic inclusions, and 290 
eccentric and pyknotic nuclei. Haematoxylin-eosin. Bars = 25µm. 291 
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 292 
 293 
 294 
Figure 2: Immunohistochemical localisation of SNAP (a-c), Syb (d-f) and Syn (g-i) in CCG 295 
from control (a, d, g), botulism (b, e, h) and EGS (c, f, i) horses. Neurons from botulism and 296 
control horses were unlabelled or had faint punctate labelling confined to axons and to 297 
clusters of granules within soma. Neurons from EGS horses had variable intensity and 298 
distribution of labelling, but the intensity of labelling for all three proteins was increased 299 
compared with that for botulism and control horses. 300 
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 301 
 302 
 303 
Figure 3: Immunohistochemical localisation of Syb in submucosal plexus neurons from (a) 304 
control, (b) botulism and (c) EGS horses. Syb immunoreactivity is confined mainly to axons 305 
in botulism and control horses, while neuronal perikarya from EGS horses have increased Syb 306 
immunoreactivity. Neuronal perikarya are labelled with short solid arrows, while long broken 307 
arrows label axons. 308 
 309 
 310 
 15 
Figure 4: QFWB confirmed increased expression of synaptic proteins Syn (Panel A&C), Syb 311 
(Panel A&D) and SNAP-25 (Panel A&E) in CCG of EGS horses (n=6) relative to controls 312 
(CTRL, n=6). Total protein stained gel (A - top panel) demonstrates uniform sample loading 313 
and is confirmed by quantification (Panel B). ** P=0.0066, *** P=0.0008, NS=non-314 
significant. 315 
 316 
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